HRP20030911A2 - Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene - Google Patents

Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene

Info

Publication number
HRP20030911A2
HRP20030911A2 HR20030911A HRP20030911A HRP20030911A2 HR P20030911 A2 HRP20030911 A2 HR P20030911A2 HR 20030911 A HR20030911 A HR 20030911A HR P20030911 A HRP20030911 A HR P20030911A HR P20030911 A2 HRP20030911 A2 HR P20030911A2
Authority
HR
Croatia
Prior art keywords
sup
triazatetracyclo
pentaene
hexadeca
citrate salt
Prior art date
Application number
HR20030911A
Other languages
English (en)
Inventor
Phillip James Johnson
Peter Robert Rose
Lewin Theophilus Wint
Glenn Robert Williams
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030911(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP20030911A2 publication Critical patent/HRP20030911A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
HR20030911A 2001-05-14 2002-04-26 Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene HRP20030911A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14
PCT/IB2002/001450 WO2002092597A1 (en) 2001-05-14 2002-04-26 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
HRP20030911A2 true HRP20030911A2 (en) 2004-02-29

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030911A HRP20030911A2 (en) 2001-05-14 2002-04-26 Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene

Country Status (37)

Country Link
US (1) US6787549B2 (forum.php)
EP (1) EP1390366B1 (forum.php)
JP (1) JP4137645B2 (forum.php)
KR (1) KR20040008175A (forum.php)
CN (1) CN1509288A (forum.php)
AP (1) AP1429A (forum.php)
AR (1) AR035889A1 (forum.php)
AT (1) ATE303386T1 (forum.php)
BG (1) BG108344A (forum.php)
CA (1) CA2446988A1 (forum.php)
CZ (1) CZ20032917A3 (forum.php)
DE (1) DE60205888T2 (forum.php)
DO (1) DOP2002000390A (forum.php)
DZ (1) DZ3503A1 (forum.php)
EA (1) EA005529B1 (forum.php)
EE (1) EE200300557A (forum.php)
ES (1) ES2245731T3 (forum.php)
GT (1) GT200200081A (forum.php)
HR (1) HRP20030911A2 (forum.php)
HU (1) HUP0304085A3 (forum.php)
IL (1) IL157874A0 (forum.php)
IS (1) IS6956A (forum.php)
MA (1) MA27021A1 (forum.php)
MX (1) MXPA03010365A (forum.php)
MY (1) MY134123A (forum.php)
NO (1) NO20035035D0 (forum.php)
NZ (1) NZ528209A (forum.php)
OA (1) OA12600A (forum.php)
PA (1) PA8545001A1 (forum.php)
PE (1) PE20021095A1 (forum.php)
PL (1) PL366774A1 (forum.php)
SK (1) SK13372003A3 (forum.php)
TN (1) TNSN03112A1 (forum.php)
UA (1) UA73421C2 (forum.php)
UY (1) UY27287A1 (forum.php)
WO (1) WO2002092597A1 (forum.php)
ZA (1) ZA200307234B (forum.php)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286886B6 (sk) * 1997-12-31 2009-07-06 Pfizer Products Inc. Azapolycyklické zlúčeniny s anelovanou arylskupinou, ich použitie, farmaceutické kompozície na ich báze a medziprodukty
BR0214806A (pt) 2001-11-30 2004-09-14 Pfizer Prod Inc Composições farmacêuticos de 5,7,14-triazatetraciclo-{10.3.1.02,11.0,4,9]-hexadeca-2(1 1),3,5,7,9-penteno
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
WO2009143347A2 (en) 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
CN102282148B (zh) * 2008-12-11 2014-12-24 Cti生物医药有限公司 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
WO2010151524A1 (en) 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
EP2837632B1 (en) 2012-04-13 2016-05-18 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) * 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
CN115968283B (zh) * 2020-03-16 2024-11-22 成都科岭源医药技术有限公司 5-ht3受体调节剂、晶型、制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286886B6 (sk) * 1997-12-31 2009-07-06 Pfizer Products Inc. Azapolycyklické zlúčeniny s anelovanou arylskupinou, ich použitie, farmaceutické kompozície na ich báze a medziprodukty
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
PL366774A1 (en) 2005-02-07
UA73421C2 (en) 2005-07-15
US6787549B2 (en) 2004-09-07
ATE303386T1 (de) 2005-09-15
CA2446988A1 (en) 2002-11-21
MXPA03010365A (es) 2004-03-16
CZ20032917A3 (cs) 2004-07-14
OA12600A (en) 2006-06-09
ZA200307234B (en) 2004-09-16
AP2002002522A0 (en) 2002-06-30
EP1390366B1 (en) 2005-08-31
EA200301120A1 (ru) 2004-02-26
US20030149091A1 (en) 2003-08-07
CN1509288A (zh) 2004-06-30
PA8545001A1 (es) 2003-09-05
HUP0304085A2 (en) 2004-04-28
UY27287A1 (es) 2003-02-28
GT200200081A (es) 2003-04-22
TNSN03112A1 (fr) 2005-12-23
MA27021A1 (fr) 2004-12-20
JP4137645B2 (ja) 2008-08-20
DE60205888D1 (de) 2005-10-06
KR20040008175A (ko) 2004-01-28
SK13372003A3 (sk) 2004-08-03
ES2245731T3 (es) 2006-01-16
BG108344A (bg) 2004-12-30
NO20035035L (no) 2003-11-13
IS6956A (is) 2003-09-15
MY134123A (en) 2007-11-30
IL157874A0 (en) 2004-03-28
AP1429A (en) 2005-06-13
NZ528209A (en) 2004-09-24
EP1390366A1 (en) 2004-02-25
JP2004529186A (ja) 2004-09-24
HUP0304085A3 (en) 2005-09-28
PE20021095A1 (es) 2002-12-14
EA005529B1 (ru) 2005-04-28
AR035889A1 (es) 2004-07-21
EE200300557A (et) 2004-04-15
NO20035035D0 (no) 2003-11-13
DOP2002000390A (es) 2003-03-15
WO2002092597A1 (en) 2002-11-21
DE60205888T2 (de) 2006-07-06
DZ3503A1 (forum.php) 2002-11-21

Similar Documents

Publication Publication Date Title
HRP20030911A2 (en) Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0&lt;sup&gt;2,11&lt;/sup&gt;.0&lt;sup&gt;4,9&lt;/sup&gt;)-hexadeca-2 (11), 3,5,7,9-pentaene
SI1392307T1 (sl) Tartrati 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)-heksadeka-2(11),3, 5,7,9-pentaena
ZA200410015B (en) Pharmaceutical salts.
IL153508A0 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
IL161857A0 (en) Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
ZA200400926B (en) Diamine derivatives.
MXPA03009728A (es) Solucion oral de aripiprazol.
MXPA03008590A (es) Derivados del factor vii de coagulacion.
ZA200203252B (en) Process for preparing 4&#34;-substituted-9-deoxo-9A-AZA-9A-homoerythromycina derivatives.
MXPA03005302A (es) Solucion acuosa para remover pintura.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
GB0130553D0 (en) 1,4-Dihydro-1,4-diphenylpyridine derivitives
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
ZA200404807B (en) Imidazoquinoline derivatives.
MXPA03008394A (es) Derivados de biuretano.
MXPA03007242A (es) Delta-1-pirrolinas para control de pestes.
PL370505A1 (en) Substituted 1,5-diaminopentan-3-ol compounds
Reinhart Dūnam pō ūmilHamā šam
IL159965A0 (en) Novel 2,4-diaminothiazole derivatives
Reinhart Nakōn lašěnī ha-‛ amīm
Reinhart Lō rāynū, lō yědānū
Reinhart Mī ken měsūgal lěmamaš’et Hazōn Šarōn?
Reinhart Mishaq ha-dimā‛ ōt
Reinhart ToKnīt Šarōn—Ya-‛ Alōn bapituaH
Reinhart Lěha-‛ avīr’et rō ha-baHīrā

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn